Home Stock

Stock Research: bioMerieux

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

bioMerieux

ENXTPA:BIM FR0013280286
91
  • Value
    81
  • Growth
    55
  • Safety
    Safety
    50
  • Combined
    85
  • Sentiment
    77
  • 360° View
    360° View
    91
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

BioMerieux SA specializes in in-vitro diagnostics for medical and industrial applications. The company operates in the medical diagnostics and industrial analysis industries. It has subsidiaries in France, Germany, Austria, and other countries. In the last fiscal year, the company had a market cap of $16,227 million, profits of $2,294 million, and revenue of $4,120 million, with 14,754 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 91 (better than 91% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock bioMerieux are very positive. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for bioMerieux. The consolidated Value Rank has an attractive rank of 50, which means that the share price of bioMerieux is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 50% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 55, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 81. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 77. ...read more

more
Country France
Industry Health Care Equipment
Size Large
Website biomerieux.fr
Index
CAC All
SBF 120
Human Rights
Recycling
SDG 10
SDG 12
SDG 13
SDG 3
SDG 8
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
50 62 67 77
Growth
55 70 31 25
Safety
Safety
81 93 90 85
Sentiment
77 88 65 79
360° View
360° View
91 100 86 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
30 47 59 69
Opinions Change
58 68 61 50
Pro Holdings
n/a 87 90 17
Market Pulse
92 73 18 92
Sentiment
77 88 65 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
50 62 67 77
Growth
55 70 31 25
Safety Safety
81 93 90 85
Combined
85 100 86 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
34 40 47 50
Price vs. Earnings (P/E)
46 52 52 72
Price vs. Book (P/B)
50 44 52 61
Dividend Yield
47 53 51 43
Value
50 62 67 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
38 60 42 16
Profit Growth
60 73 37 64
Capital Growth
40 56 34 37
Stock Returns
63 64 57 35
Growth
55 70 31 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
76 72 78 65
Refinancing
48 45 43 40
Liquidity
89 92 92 94
Safety Safety
81 93 90 85

Similar Stocks

Discover high‑ranked alternatives to bioMerieux and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Compagnie des Alpes

ENXTPA:CDA
Country: France
Industry: Leisure Facilities
Size: Medium
Full Stock Analysis

Synergie

ENXTPA:SDG
Country: France
Industry: HR- & Employment Services
Size: Medium
Full Stock Analysis

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis
OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.